3.2 Oncology

Introduction to Oncology for USMLE

Oncology within the USMLE context focuses on how cancers present, how they are investigated, and what practical decisions a new doctor is expected to make. You are not expected to be an oncologist, but you must recognize red‑flag patterns, understand basic diagnostic steps, and know first‑line management principles and their complications. Systemic and molecular aspects of neoplasia are covered elsewhere, so this chapter focuses on how oncology appears in organ‑based, clinical questions.

On USMLE, oncology questions often integrate pathology, pharmacology, genetics, and ethics. You are commonly given a patient with vague symptoms, laboratory or imaging findings, and you must suspect malignancy early, select an appropriate next test, or identify an urgent complication of cancer or its treatment. This chapter will help you see recurring clinical patterns and link them with key exam‑relevant decisions.

Red Flag Features Suggesting Cancer

On clinical vignettes, certain patterns should always trigger consideration of malignancy. These findings are not specific, but the exam expects you to recognize when cancer must be ruled out. You will then choose appropriate investigations or referrals.

Important systemic red flags include unintentional weight loss, anorexia, night sweats, and persistent fatigue. When such symptoms persist beyond a few weeks, especially in an older patient or someone with risk factors like smoking, chronic inflammation, or family history, you must consider cancer, infection, or autoimmune disease. Recurrent or nonresolving symptoms despite appropriate initial treatment are particularly suspicious.

Local red flags relate to specific organs. Persistent cough with hemoptysis, especially in a smoker or someone with environmental exposure, should immediately raise concern for lung cancer. A changing skin lesion with asymmetry, irregular borders, color variation, and diameter growth suggests melanoma. A painless testicular mass, even in a young man, is considered testicular cancer until proven otherwise. Painless jaundice in an older patient often suggests pancreatic or biliary malignancy rather than benign stones.

Lymphadenopathy is a classic clue. Tender, soft lymph nodes are frequent in benign infections. Hard, fixed, non‑tender nodes, especially in the supraclavicular region, are much more concerning for malignancy such as lymphoma or metastatic disease. Generalized lymphadenopathy with night sweats and weight loss points toward hematologic cancers like Hodgkin lymphoma or chronic lymphocytic leukemia.

USMLE questions often test your ability to recognize a gradual pattern of symptom accumulation. For example, a patient with progressive dysphagia to solids then liquids, weight loss, and long‑standing gastroesophageal reflux disease is at risk for esophageal adenocarcinoma. Another patient with postmenopausal bleeding, obesity, and unopposed estrogen exposure has elevated risk for endometrial carcinoma. You are expected to connect these symptom clusters with an underlying malignant process and move quickly to diagnostic procedures such as endoscopy or biopsy.

Cancer Staging, Grade, and Prognosis

For USMLE purposes, staging and grading matter because they drive prognosis and treatment choices. Although Systemic Pathology discusses these concepts in depth, here you should focus on how staging and grade affect common decisions in clinical oncology questions.

Staging describes how far a cancer has spread in the body. The TNM system is commonly used. T refers to the size and depth of local tumor invasion, N to involvement of regional lymph nodes, and M to the presence of distant metastases. For example, a localized breast tumor with no nodal involvement and no metastasis is early stage, while a primary lung cancer with liver and brain lesions is stage IV with M1 disease. USMLE questions often ask you to choose appropriate therapies based on whether a cancer is localized, regionally advanced, or metastatic.

Tumor grade reflects how abnormal the cancer cells look under the microscope compared to normal tissue. Low‑grade tumors resemble their tissue of origin and tend to grow more slowly. High‑grade tumors are poorly differentiated, appear very abnormal, and often behave aggressively. In vignettes, a “poorly differentiated carcinoma” or “high‑grade lymphoma” usually suggests rapid progression and a worse prognosis, which justifies more intensive therapy if the patient can tolerate it.

Staging is generally more important than grade in determining overall prognosis and treatment. A high‑grade tumor that is small and has not spread can sometimes be cured with local therapy and appropriate systemic treatment. In contrast, even a well‑differentiated tumor that has already metastasized widely is usually not curable by surgery alone. USMLE questions may ask things such as which factor most strongly predicts survival, and staging, especially nodal and metastatic status, is typically the best answer in solid tumors.

In many organ systems, such as colon, lung, breast, and prostate, the presence or absence of lymph node metastasis is a major breakpoint between early and more advanced stages. That can determine whether adjuvant chemotherapy or radiation is recommended after surgery. Recognizing statements like “positive sentinel lymph node” or “multiple involved axillary nodes” is key to identifying a higher stage.

Principles of Cancer Diagnosis

Clinical oncology begins with suspicion, then confirmation with histologic diagnosis. On the USMLE, you should know the general logic of choosing between imaging, endoscopy, and biopsy, and in what sequence they are usually performed.

Biopsy is the gold standard for diagnosing most solid tumors. Imaging alone is rarely sufficient. For example, a solitary pulmonary nodule seen on chest CT in an older smoker should prompt a tissue diagnosis. The best approach depends on location. Peripheral lung lesions are often sampled with CT‑guided transthoracic needle biopsy. Central lesions are more accessible by bronchoscopy with biopsy. For accessible masses such as breast or thyroid nodules, a core needle or fine needle aspiration biopsy is commonly used.

Certain sites require endoscopic biopsies. Suspicious gastric or colonic lesions are sampled through upper endoscopy or colonoscopy. A patient with rectal bleeding and iron deficiency anemia often undergoes colonoscopy first. If a mass is found, tissue is taken for pathology. In the esophagus, progressive dysphagia with weight loss typically leads to an upper endoscopy with biopsy rather than empirical therapy alone.

Imaging plays an essential role in initial evaluation and staging. Ultrasound is often the first test for liver lesions, thyroid nodules, or pelvic masses because it is noninvasive and does not involve ionizing radiation. CT is widely used to evaluate thoracic, abdominal, and pelvic malignancies, while MRI has advantages in brain, spinal, and soft tissue tumors. PET scanning, especially PET‑CT, is commonly used to detect metabolically active metastases, particularly in lymphoma and some solid tumors, although you are not expected to memorize detailed PET protocols.

Cytology and body fluid analysis are useful in certain situations. For example, pleural effusion in a patient with a known lung or breast cancer should raise suspicion for malignant effusion. Thoracentesis with cytology can reveal malignant cells, which indicates more advanced disease and changes staging. Similarly, ascitic fluid can be sampled in suspected ovarian or gastrointestinal cancers.

Blood tests alone are usually not enough to diagnose solid cancers, but they support clinical reasoning. New‑onset anemia, especially iron deficiency in an older adult, should prompt a search for gastrointestinal malignancy. Elevated liver enzymes or cholestatic patterns might suggest hepatic or biliary involvement. Tumor markers, discussed elsewhere, are rarely used for initial diagnosis in USMLE questions, but they are sometimes used for monitoring disease course.

In hematologic malignancies such as leukemia and lymphoma, blood smear, bone marrow biopsy, and specialized studies such as flow cytometry and cytogenetics are central. On the exam, a persistent leukocytosis with abnormal cells in peripheral blood and systemic symptoms like fever and night sweats usually requires bone marrow examination for definitive diagnosis, not just repeat complete blood counts.

Treatment Modalities in Clinical Oncology

In practice, oncologic treatment is often multimodal. Most USMLE scenarios require you to select the dominant or next best treatment modality given a specific clinical context and stage. You should know only the broad roles of each approach and recognize classic situations where they are first line.

Surgery is usually the main curative option for localized solid tumors when complete resection is feasible and the patient is fit. Early stage colon cancer, localized non‑small cell lung cancer, and early breast cancer are often treated with surgical removal, sometimes including lymph node sampling. Surgery can also be palliative, for example to relieve bowel obstruction from a colon tumor that is not otherwise curable.

Radiation therapy is used for local control, either with or instead of surgery, and for palliation. For example, localized prostate cancer can be treated with external beam radiation. Brain metastases often receive whole‑brain or stereotactic radiation. Palliative radiation is a classic choice for painful bone metastases when systemic cure is not possible but symptom relief is needed.

Systemic therapy includes chemotherapy, targeted therapy, hormonal therapy, and immunotherapy. Traditional cytotoxic chemotherapy is used both with curative intent, for example in Hodgkin lymphoma or testicular cancer, and with palliative intent in metastatic disease such as pancreatic or colon cancer. Chemotherapy can be given before surgery as neoadjuvant therapy to shrink tumors, or after surgery as adjuvant therapy to destroy microscopic residual disease that might cause recurrence.

Hormonal therapies are particularly important in hormone sensitive cancers. Estrogen receptor positive breast cancer is commonly treated with drugs that block estrogen effects or reduce estrogen production, such as selective estrogen receptor modulators or aromatase inhibitors, in addition to surgery and possible chemotherapy. Prostate cancer is treated with androgen deprivation therapy, often in combination with radiation or surgery.

Targeted therapies and immunotherapies, while discussed in Pharmacology, appear in oncology vignettes as drugs selected for cancers with specific molecular features. For example, a non‑small cell lung cancer with an EGFR mutation may respond to an EGFR inhibitor, while some melanomas with BRAF mutations can be treated with BRAF inhibitors. Checkpoint inhibitors, such as antibodies against PD‑1 or CTLA‑4, enhance immune response against tumor cells and have characteristic immune related adverse events like colitis or dermatitis that you need to recognize.

Choosing between curative and palliative intent is an important exam theme. For early stage disease in a fit patient, aggressive combined modality treatment may be justified to achieve cure. In advanced metastatic disease with poor performance status, the more appropriate focus may be symptom control, pain relief, and quality of life rather than intensive regimens with serious toxicity.

Common Oncologic Emergencies

Oncologic emergencies are high‑yield on USMLE because they require rapid recognition and specific immediate management. You must be able to identify the pattern in a vignette and choose the correct life saving intervention.

One of the most frequently tested is tumor lysis syndrome, which occurs when large numbers of tumor cells break down rapidly, commonly after initiation of chemotherapy in highly proliferative malignancies such as acute leukemias and high‑grade lymphomas. Cell lysis releases potassium, phosphate, and nucleic acids. Nucleic acids are metabolized to uric acid, which can precipitate in the kidneys. Laboratory abnormalities include hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia, often with acute kidney injury.

Hypercalcemia of malignancy is another common emergency. It can result from bone metastases causing osteolysis or from humoral factors such as PTH related peptide secreted by certain cancers like squamous cell carcinomas. Patients may present with polyuria, polydipsia, constipation, confusion, and muscle weakness. On exam questions, chronic hypercalcemia from malignancy often appears in older patients with weight loss and a known or suspected cancer. Initial management includes aggressive intravenous fluids, sometimes loop diuretics after adequate hydration, and agents that inhibit bone resorption such as bisphosphonates.

Spinal cord compression is a feared complication of metastatic cancer, particularly from breast, lung, and prostate primaries, as well as multiple myeloma. Typical symptoms are back pain, often worse at night or with coughing, and neurologic deficits such as weakness, sensory loss, or bowel/bladder dysfunction. On USMLE, this is an emergency that requires immediate corticosteroids to reduce edema, followed by MRI of the spine and urgent consultation for possible radiation or surgical decompression. Delay can lead to irreversible paralysis.

Superior vena cava syndrome results from obstruction of the superior vena cava, most often due to tumor compression or thrombosis in the context of lung cancer or mediastinal masses. Patients can present with facial swelling, distended neck veins, dyspnea, and sometimes headache or visual disturbances. Management focuses on treating the underlying cause, often with radiation or chemotherapy, and supportive care. While it is serious, immediate airway and neurologic threats such as spinal cord compression and airway obstruction often take priority.

Neutropenic fever is one of the most important emergencies related to cancer treatment. It typically appears in a patient on cytotoxic chemotherapy whose absolute neutrophil count falls below 500 per microliter, followed by fever without a clear source. Because such patients have impaired inflammatory responses, they can deteriorate quickly. The key is prompt administration of broad spectrum intravenous antibiotics that cover gram negative organisms, including Pseudomonas, even before a specific source is identified.

Massive pulmonary embolism can occur in patients with cancer because malignancy is a strong risk factor for venous thromboembolism. Sudden onset dyspnea, pleuritic chest pain, tachycardia, and hypotension in a cancer patient should raise concern for pulmonary embolism. In hemodynamically unstable patients, systemic thrombolysis or other advanced interventions may be appropriate, while anticoagulation is used in more stable cases.

Paraneoplastic Syndromes in Clinical Context

Paraneoplastic syndromes are systemic manifestations caused by a cancer, but not directly due to local presence or metastasis of the tumor. They are exam favorites because they can be the first clue to an otherwise occult malignancy. Recognizing the association between a particular syndrome and an underlying cancer type is critical.

One classic paraneoplastic syndrome is Lambert Eaton myasthenic syndrome, which causes proximal muscle weakness that improves with repeated use. It is associated with antibodies against presynaptic calcium channels at the neuromuscular junction. This syndrome is strongly linked with small cell lung cancer. In a vignette, a smoker with subacute proximal weakness, autonomic symptoms like dry mouth, and areflexia may have Lambert Eaton syndrome, prompting a search for an underlying small cell carcinoma.

Endocrine paraneoplastic syndromes are also common. Ectopic ACTH production by small cell lung cancer can lead to Cushing syndrome with central obesity, proximal muscle weakness, hypertension, and skin changes. Another example is ectopic ADH secretion by small cell carcinoma, resulting in hyponatremia and associated neurologic symptoms. Hypercalcemia mediated by PTH related peptide secretion, especially from squamous cell carcinomas, is another. In each, the hormonal abnormality does not match feedback physiology or pituitary findings.

Neurologic paraneoplastic syndromes can be subtle but important. Subacute cerebellar degeneration presents with progressive ataxia, dysarthria, and nystagmus. It is often associated with antibodies against neuronal antigens in the context of gynecologic or breast malignancies, or small cell lung cancer. These syndromes are usually not due to direct brain metastases and often have normal imaging initially.

Dermatologic manifestations such as acanthosis nigricans can be paraneoplastic when they arise suddenly and extensively in an older patient, often associated with gastric adenocarcinoma or other gastrointestinal cancers. Similarly, dermatomyositis with characteristic rash distribution and muscle weakness can be linked with an underlying malignancy. On USMLE, such findings should prompt you to investigate for internal cancers rather than treat them as purely idiopathic disorders.

Paraneoplastic hematologic manifestations are also important. Migratory superficial thrombophlebitis, known as Trousseau syndrome, is linked with pancreatic and other visceral malignancies. A patient with unexplained recurrent venous thromboses or superficial vein inflammation should lead you to consider an occult cancer workup.

In vignettes, paraneoplastic clues often precede detection of a tumor. The exam expects you to think in both directions. When you see an unusual syndrome, you should suspect an underlying malignancy. When a cancer is already diagnosed, you should recognize when new systemic findings are due to a paraneoplastic process rather than direct invasion, metastasis, or drug side effect, because that influences both testing and management.

Screening and Early Detection

Screening is integral to clinical oncology because many solid tumors are more curable when detected early. For USMLE, you must know the basic principles of screening, not every guideline detail. Screening aims to identify disease in asymptomatic individuals at sufficient risk where early intervention improves outcomes more than harms.

The exam commonly tests established cancer screening programs such as mammography for breast cancer, colonoscopy for colorectal cancer, and Pap testing for cervical cancer. While the exact ages and intervals may vary slightly by guideline, the logic is consistent. High risk patients, such as those with hereditary cancer syndromes or strong family histories, often start screening earlier or use more sensitive tests. In contrast, screening is not usually recommended in patients with limited life expectancy, where harms may outweigh benefits.

You should also distinguish screening from diagnostic evaluation. Screening applies to asymptomatic patients. Once symptoms appear, such as rectal bleeding, a diagnostic test is indicated regardless of screening schedule. In USMLE questions, this distinction emerges when choosing the next step. For example, a 55 year old asymptomatic person may be offered colon cancer screening. However, a 55 year old with hematochezia and iron deficiency anemia needs diagnostic colonoscopy, not just stool based screening.

Some cancers have effective early detection strategies in selected high risk groups. For example, individuals with chronic hepatitis B or cirrhosis are often monitored for hepatocellular carcinoma with ultrasound and serum alpha fetoprotein levels. Heavy smokers with long smoking histories may undergo low dose CT screening for lung cancer. In such cases, personal risk factors heavily influence whether screening is appropriate.

The harms of screening, including false positives, overdiagnosis, and anxiety, are also tested conceptually. PSA testing for prostate cancer is a common example where potential benefits must be weighed against risks like overdiagnosis of indolent cancers and complications of biopsy and treatment. In older patients with significant comorbidities and limited life expectancy, continuing screening often offers little benefit.

Finally, public health and preventive oncology link cancer screening with vaccination and lifestyle modification. For example, HPV vaccination reduces the risk of cervical and other anogenital cancers, and smoking cessation decreases risk of lung and many other cancers. On USMLE, recognizing patients who still benefit from preventive counseling and vaccination, even in midlife, is an important aspect of oncologic care.

Psychosocial and Ethical Aspects of Cancer Care

Cancer care involves complex emotional and ethical issues that are frequently tested in behavioral and clinical skills contexts. As a future physician, the way you communicate diagnoses, address patient values, and handle end‑of‑life decisions is as important as selecting chemotherapy regimens.

Delivering a diagnosis of cancer must be done honestly, with empathy, and in language that the patient can understand. You are expected to assess how much information the patient wishes to receive, invite questions, and respond to emotions rather than focusing only on facts. Questions often test your ability to avoid false reassurance, to avoid giving prognosis before understanding patient preferences, and to include families only with the patient’s consent.

Decision making in oncology often involves discussing treatment options that offer small benefits at the cost of substantial side effects. Respect for patient autonomy means you must present alternatives fairly, including palliative care and hospice when appropriate. On vignettes, the best answer usually involves first exploring the patient’s goals and values before recommending aggressive interventions. Statements like “help me live long enough to attend my daughter’s wedding” or “I do not want to be a burden” should shape the care plan.

End‑of‑life care is particularly relevant. When cure is no longer possible, shifting goals to comfort, symptom control, and quality of life is ethically appropriate. Some patients may decline further chemotherapy. On USMLE, you should respect competent refusals and not pressure patients to accept treatments that conflict with their values. Discussions about code status, resuscitation, and advanced directives are integral parts of oncology care.

Cultural factors influence how patients understand and cope with cancer. Some cultures avoid direct discussion of terminal illness, while others expect full disclosure. The exam often expects a balance where you respect cultural norms but still honor the individual patient’s right to know. It is usually best to ask the patient how they want information to be shared rather than assuming based on background.

Finally, cancer survivorship brings its own psychosocial challenges. Patients may experience anxiety about recurrence, body image concerns after surgery or radiation, and functional limitations due to long term treatment effects. Even when the exam focuses on acute presentations, remember that recognizing depression, anxiety, and other psychological reactions in cancer patients is part of comprehensive oncologic care, and referral to counseling or support groups is often an appropriate next step.

Integrating Oncology Across Organ Systems

Oncology appears in nearly every organ system chapter, so it is helpful to view this chapter as a framework for integrating what you learn elsewhere. Each organ system has its own typical malignancies, risk factors, presentations, and preferred treatments. Your task for the exam is to apply a consistent clinical reasoning process regardless of the organ involved.

First, identify risk factors and red flags that suggest cancer in that particular system, such as chronic hepatitis in hepatic tumors or long term smoking in lung cancer. Second, determine the best initial diagnostic step and the definitive test, often some form of biopsy. Third, consider staging to distinguish localized from advanced disease, then choose realistic treatment options such as surgery, radiation, or systemic therapy. Finally, always remain alert to oncologic emergencies and paraneoplastic manifestations that might appear elsewhere in the body.

By practicing this same structured approach across cardiovascular, respiratory, gastrointestinal, endocrine, and other systems, you will be better prepared to tackle the wide range of oncology questions that appear throughout the USMLE exams.